Tags

Type your tag names separated by a space and hit enter

Frequency and outcome of pediatric acute lymphoblastic leukemia with ZNF384 gene rearrangements including a novel translocation resulting in an ARID1B/ZNF384 gene fusion.
Pediatr Blood Cancer 2016; 63(11):1915-21PB

Abstract

BACKGROUND

ZNF384 gene rearrangements with multiple partner genes are recurrent in acute leukemia and are most often associated with a precursor B cell immunophenotype. The overall incidence of this genetic category of leukemia is uncertain.

PROCEDURE

Patients with ZNF384 gene rearrangements from a cohort of 240 precursor B cell acute lymphoblastic leukemia (ALL) pediatric patients over a 3.5-year time period were characterized with detailed cytogenetic, FISH, genomic, and clinical analyses.

RESULTS

Seven of the 240 patients were identified to have ZNF384 gene rearrangements including partner genes TCF3 (four patients), EWSR1 (one patient), EP300 (one patient), and the novel gene partner ARID1B (one patient). The translocations were confirmed by FISH analysis and with RNA sequencing for the EP300 and ARID1B partner genes. Genomic microarray analysis showed an average of 2.7 copy number alterations in each case with no evidence of imbalance at the translocation breakpoints. Six of the patients with ZNF384 gene rearrangements had precursor B cell ALL with a CD10- immunophenotype and myeloid-associated antigens. One of the patients also had myeloperoxidase expression and was diagnosed as mixed phenotype B/myeloid acute leukemia. None of the patients have relapsed with event-free survival ranging from 6 years 2 months to 9 years 2 months.

CONCLUSIONS

This study suggests that the frequency of ZNF384 gene rearrangement in pediatric precursor B cell ALL is approximately 3%. The ARID1B gene, commonly mutated in multiple types of cancer, was identified as an additional ZNF384 gene fusion partner.

Authors+Show Affiliations

Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada. mary.shago@sickkids.ca. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. mary.shago@sickkids.ca.Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada. Department of Pediatrics, University of Toronto, Toronto, Canada.Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada. Department of Pediatrics, University of Toronto, Toronto, Canada.Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada. Department of Pediatrics, University of Toronto, Toronto, Canada.Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27392123

Citation

Shago, Mary, et al. "Frequency and Outcome of Pediatric Acute Lymphoblastic Leukemia With ZNF384 Gene Rearrangements Including a Novel Translocation Resulting in an ARID1B/ZNF384 Gene Fusion." Pediatric Blood & Cancer, vol. 63, no. 11, 2016, pp. 1915-21.
Shago M, Abla O, Hitzler J, et al. Frequency and outcome of pediatric acute lymphoblastic leukemia with ZNF384 gene rearrangements including a novel translocation resulting in an ARID1B/ZNF384 gene fusion. Pediatr Blood Cancer. 2016;63(11):1915-21.
Shago, M., Abla, O., Hitzler, J., Weitzman, S., & Abdelhaleem, M. (2016). Frequency and outcome of pediatric acute lymphoblastic leukemia with ZNF384 gene rearrangements including a novel translocation resulting in an ARID1B/ZNF384 gene fusion. Pediatric Blood & Cancer, 63(11), pp. 1915-21. doi:10.1002/pbc.26116.
Shago M, et al. Frequency and Outcome of Pediatric Acute Lymphoblastic Leukemia With ZNF384 Gene Rearrangements Including a Novel Translocation Resulting in an ARID1B/ZNF384 Gene Fusion. Pediatr Blood Cancer. 2016;63(11):1915-21. PubMed PMID: 27392123.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Frequency and outcome of pediatric acute lymphoblastic leukemia with ZNF384 gene rearrangements including a novel translocation resulting in an ARID1B/ZNF384 gene fusion. AU - Shago,Mary, AU - Abla,Oussama, AU - Hitzler,Johann, AU - Weitzman,Sheila, AU - Abdelhaleem,Mohamed, Y1 - 2016/07/08/ PY - 2016/04/05/received PY - 2016/05/17/revised PY - 2016/05/31/accepted PY - 2016/7/9/entrez PY - 2016/7/9/pubmed PY - 2017/6/18/medline KW - FISH KW - RNA sequencing KW - cytogenetics KW - precursor B cell acute lymphoblastic leukemia SP - 1915 EP - 21 JF - Pediatric blood & cancer JO - Pediatr Blood Cancer VL - 63 IS - 11 N2 - BACKGROUND: ZNF384 gene rearrangements with multiple partner genes are recurrent in acute leukemia and are most often associated with a precursor B cell immunophenotype. The overall incidence of this genetic category of leukemia is uncertain. PROCEDURE: Patients with ZNF384 gene rearrangements from a cohort of 240 precursor B cell acute lymphoblastic leukemia (ALL) pediatric patients over a 3.5-year time period were characterized with detailed cytogenetic, FISH, genomic, and clinical analyses. RESULTS: Seven of the 240 patients were identified to have ZNF384 gene rearrangements including partner genes TCF3 (four patients), EWSR1 (one patient), EP300 (one patient), and the novel gene partner ARID1B (one patient). The translocations were confirmed by FISH analysis and with RNA sequencing for the EP300 and ARID1B partner genes. Genomic microarray analysis showed an average of 2.7 copy number alterations in each case with no evidence of imbalance at the translocation breakpoints. Six of the patients with ZNF384 gene rearrangements had precursor B cell ALL with a CD10- immunophenotype and myeloid-associated antigens. One of the patients also had myeloperoxidase expression and was diagnosed as mixed phenotype B/myeloid acute leukemia. None of the patients have relapsed with event-free survival ranging from 6 years 2 months to 9 years 2 months. CONCLUSIONS: This study suggests that the frequency of ZNF384 gene rearrangement in pediatric precursor B cell ALL is approximately 3%. The ARID1B gene, commonly mutated in multiple types of cancer, was identified as an additional ZNF384 gene fusion partner. SN - 1545-5017 UR - https://www.unboundmedicine.com/medline/citation/27392123/Frequency_and_outcome_of_pediatric_acute_lymphoblastic_leukemia_with_ZNF384_gene_rearrangements_including_a_novel_translocation_resulting_in_an_ARID1B/ZNF384_gene_fusion_ L2 - https://doi.org/10.1002/pbc.26116 DB - PRIME DP - Unbound Medicine ER -